"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Case report
peer-reviewed

Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis



Abstract

In breast cancer, aggressive tumor biology and the corresponding poor prognosis is associated with amplification or overexpression of the human epidermal growth factor receptor 2 (HER2). Trastuzumab has significantly changed the natural history of HER2-positive breast cancer. However, resistance to trastuzumab remains a substantial clinical problem. Ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate, has demonstrated impressive results in second- or later-line treatment of HER2-positive breast cancer. We report a case of 43-year-old female with previously trastuzumab-treated HER2-positive breast cancer relapsed with pulmonary lymphangitis carcinomatosis that responded dramatically to T-DM1 therapy. 



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Case report
peer-reviewed

Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis


Author Information

Zhou Yu Corresponding Author

Department of Hematology Oncology, William Beaumont Hospital, Oakland University William Beaumont School of Medicine

Shobana Sankar

Department of Internal Medicine, William Beaumont Hospital

Marianne Huben

Department of Hematology and Oncology, William Beaumont Hospital, Oakland University William Beaumont School of Medicine


Ethics Statement and Conflict of Interest Disclosures

Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: The authors have declared that no conflicts of interest exist.


Case report
peer-reviewed

Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis


Figures etc.

Share
Case report
peer-reviewed

Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis

  • Author Information
    Zhou Yu Corresponding Author

    Department of Hematology Oncology, William Beaumont Hospital, Oakland University William Beaumont School of Medicine

    Shobana Sankar

    Department of Internal Medicine, William Beaumont Hospital

    Marianne Huben

    Department of Hematology and Oncology, William Beaumont Hospital, Oakland University William Beaumont School of Medicine


    Ethics Statement and Conflict of Interest Disclosures

    Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: The authors have declared that no conflicts of interest exist.

    Acknowledgements


    Article Information

    Published: July 14, 2017

    DOI

    10.7759/cureus.1473

    Cite this article as:

    Yu Z, Sankar S, Huben M (July 14, 2017) Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis. Cureus 9(7): e1473. doi:10.7759/cureus.1473

    Publication history

    Received by Cureus: May 22, 2017
    Peer review began: May 31, 2017
    Peer review concluded: July 10, 2017
    Published: July 14, 2017

    Copyright

    © Copyright 2017
    Yu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    License

    This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

  • Categories

    Keywords

    breast cancer, trastuzumab, t-dm1, her2

Abstract

In breast cancer, aggressive tumor biology and the corresponding poor prognosis is associated with amplification or overexpression of the human epidermal growth factor receptor 2 (HER2). Trastuzumab has significantly changed the natural history of HER2-positive breast cancer. However, resistance to trastuzumab remains a substantial clinical problem. Ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate, has demonstrated impressive results in second- or later-line treatment of HER2-positive breast cancer. We report a case of 43-year-old female with previously trastuzumab-treated HER2-positive breast cancer relapsed with pulmonary lymphangitis carcinomatosis that responded dramatically to T-DM1 therapy. 



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Zhou Yu

Department of Hematology Oncology, William Beaumont Hospital, Oakland University William Beaumont School of Medicine

For correspondence:
zhou.yu@beaumont.edu

Shobana Sankar

Department of Internal Medicine, William Beaumont Hospital

Marianne Huben

Department of Hematology and Oncology, William Beaumont Hospital, Oakland University William Beaumont School of Medicine

Zhou Yu

Department of Hematology Oncology, William Beaumont Hospital, Oakland University William Beaumont School of Medicine

For correspondence:
zhou.yu@beaumont.edu

Shobana Sankar

Department of Internal Medicine, William Beaumont Hospital

Marianne Huben

Department of Hematology and Oncology, William Beaumont Hospital, Oakland University William Beaumont School of Medicine